Significant Improvement In Progression-Free Survival For Triple Negative Metastatic Breast Cancer Patients Treated With IXEMPRA™ Plus Capecitabi Bristol-Myers Squibb Company (NYSE:BMY) today announced new data from studies of IXEMPRA™ (ixabepilone) plus capecitabine compared to capectabine alone, including a pre-specified sub set analysis demonstrating a significant increase in progression free survival (PFS) in patients with triple negative breast cancer.
Source: www.medicalnewstoday.comC.B. Fleet Voluntarily Recalls Its Fleet(R) Phospho-soda(R) Products After FDA Safety Alert Following the issuance of FDA's Safety Alert on Thursday stating that oral sodium phosphates bowel cleansing solutions should be available by
prescription only, C.B. Fleet Company immediately announced a voluntary recall of their over-the-counter products Fleet® Phospho-soda® and Fleet® Phospho-soda® EZ-Prep® Bowel Cleansing System.
Source: www.medicalnewstoday.comExperimental Treatment Lengthens Lifespan Of Monkeys With Simian Version Of HIV, Study Says Macaque monkeys with simian immunodeficiency virus -- the simian equivalent of HIV -- that received a single dose of an experimental treatment survived nearly twice as long as monkeys who did not receive the drug, according to a study published Wednesday in the journal Nature, BBC News reports.
Source: www.medicalnewstoday.comBayer USA Foundation Awards $279,000 Grant To Exemplary STEM Education Diversity Program Reaffirming its longstanding commitment to help strengthen science, technology, engineering and mathematics (STEM) education and bring more women and minorities into STEM fields, the Bayer USA Foundation today awarded a $279,000 grant over three years to the nationally lauded Mathematics, Engineering
Source: www.medicalnewstoday.comAkorn, Inc. Announces FDA Approval Of Ciprofloxacin HCl Ophthalmic Solution USP, 0.3% Akorn, Inc. (NASDAQ: AKRX) today announced that the U.S. Food and Drug Administration has granted approval for Akorn's Abbreviated New Drug Application (ANDA) for Ciprofloxacin HCl Ophthalmic Solution USP, 0.3%. Ciprofloxacin HCl Ophthalmic Solution is indicated for the treatment of infections caused by microorganisms in corneal ulcers and conjunctivitis.
Source: www.medicalnewstoday.com
# posted by Network @ 8:00 AM
